Immunotherapy

FDA Grants Priority Review to Keytruda for Patients with High-Risk, Non–Muscle-Invasive Bladder Cancer

Yvette Florio Lane

Bladder Cancer, FDA Approvals, News & Updates, Immunotherapy

On December 2, 2019, Merck announced that the FDA has granted priority review for its supplemental biologics license application for the anti–PD-1 agent pembrolizumab (Keytruda). If approved, the drug would be indicated as monotherapy to treat patients with Bacillus Calmette-Guerin–unresponsive, high-risk, non–muscle-invasive bladder cancer who are ineligible for or have decided not to undergo cystectomy. [ Read More ]

Applying CAR T-Cell Therapies to Solid Tumors: Overcoming Current Challenges

Chase Doyle

August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO 2019 Highlights - Immunotherapy

Chicago, IL—Reprogramming patients’ immune cells to treat their cancer has become the front line of cancer therapy, with chimeric antigen receptor (CAR) T-cell therapy now approved by the FDA for several blood cancers. But translating this success to solid tumors remains a challenge. At ASCO 2019, ­Gianpietro Dotti, MD, Cancer Cellular Immunotherapy Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, discussed efforts to extend the application of CAR T-cell therapy to solid tumors [ Read More ]

Overcoming Current Barriers to Using CAR T-Cell Therapy in the Community Setting

Chase Doyle

August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO 2019 Highlights - Immunotherapy

Chicago, IL—With 475 cell and gene therapy companies in North America representing a business enterprise with approximately $20 billion, new immunotherapies are moving rapidly from the laboratory to the clinic. As chimeric antigen receptor (CAR) T-cell therapy makes its way from the academic to community setting, however, appropriate resources and infrastructure are required to ensure the safe and effective management of patients. [ Read More ]

Durvalumab plus Tremelimumab Immunotherapy Combination Extends Survival in Refractory Colorectal Cancer

Wayne Kuznar

June 2019, Vol 10, No 3 - Colorectal Cancer, Immunotherapy

San Francisco, CA—The combination of the PD-1 inhibitor durvalumab ­(Imfinzi) and the investigational CTLA-4 inhibitor tremelimumab plus best supportive care improved overall survival (OS) by more than 2 months versus best supportive care alone in a phase 2 clinical trial of patients with refractory colorectal cancer (CRC), reported Eric Xueyu Chen, MD, PhD, Staff Oncologist, Princess Margaret Cancer Centre, Toronto, Canada, at the 2019 Gastrointestinal Cancers Symposium. [ Read More ]

Evolving Immuno-Oncology Strategies in Renal-Cell Carcinoma

Wayne Kuznar

June 2019, Vol 10, No 3 - Immunotherapy

San Francisco, CA—The era of immunotherapy has opened new perspectives in renal-cell carcinoma (RCC), which is one of the tumors most highly infiltrated with CD T-cells and PD-1 expression, partially accounting for its sensitivity to immunotherapy. Other mechanisms to explain its sensitivity include myeloid infiltration, metabolic alterations, loss-of-function mutations, and human endogenous retroviruses. [ Read More ]

Can Immunotherapy Work in Ovarian Cancer?

Wayne Kuznar

June 2019, Vol 10, No 3 - Immunotherapy, Ovarian Cancer

San Francisco, CA—Patients with ovarian cancer can respond to immunotherapy, but rationally designed synergistic combinations will be necessary to enhance upfront efficacy and to sustain durability, said Daniel J. Powell Jr, PhD, Scientific Director of Immunotherapy, Division of Gynecologic Oncology, Center for Cellular Immunotherapy, University of Pennsylvania, Philadelphia, at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. [ Read More ]

First Positive Showing for Mesothelin-Directed CAR T-Cell Therapy in Solid Tumors

Phoebe Starr

June 2019, Vol 10, No 3 - Immunotherapy

Atlanta, GA—Chimeric antigen receptor (CAR) T-cell therapy has had dramatic results in hematologic malignancies, but so far, getting CAR T-cells to work in solid tumors has proved elusive. That may be about to change if promising results from a phase 1 clinical trial are confirmed by further studies. The results of this pivotal study were presented at the 2019 American Association for Cancer Research (AACR) annual meeting. [ Read More ]

CAR T-Cell Therapy Associated with Unique, Acute Adverse Events Requiring Vigilant Monitoring

Wayne Kuznar

April 2019, Vol 10, No 2 - Immunotherapy

San Francisco, CA—Chimeric antigen receptor (CAR) T-cell therapy is associated with unique adverse events that require vigilant monitoring, aggressive care, and specialized management. Marco L. Davila, MD, PhD, Medical Oncologist, Blood and Marrow Transplant and Cellular Immunotherapy Program, Moffitt Cancer Center, Tampa, FL, provided an overview of this topic at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. [ Read More ]

Genomic Markers of Response Improve Patient Selection for Immune Checkpoint Inhibitor Therapy

Wayne Kuznar

April 2019, Vol 10, No 2 - Immunotherapy

San Francisco, CA—Promising markers of response to immune checkpoint inhibition include tumor mutation burden (TMB) and genomic markers that reflect a disruption of the tumor immunity cycle, said Natalie Vokes, MD, MPhil, Medical Oncology Fellow, Dana-Farber Cancer Institute, Boston, at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. [ Read More ]